When compared to first-line sorafenib, the combination of atezolizumab (an anti-PD-L1) and bevacizumab (a VEGF blockade) provides superior outcomes and has become a new first-line treatment in advanced HCC [5]. Here, CD274 is linked to hepatocellular carcinoma.